{"success":true,"data":{"pressRelease":{"id":"72916","rtpr_id":"nGNX9R9c4R","ticker":"9887","exchange":"HKEX","all_tickers":["9887"],"title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development","author":"Globe Newswire","published_at":"2026-06-25T10:38:00.097Z","article_body":"NANJING, China, June 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co.,\nLtd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today\nannounced that its partner company with Aditum Bio, Oblenio Bio\n(“Oblenio”), has successfully closed an oversubscribed $62 million Series\nB financing round. The round was led by Pfizer Ventures, with participation\nfrom Deep Track Capital, GV, and founding investor Aditum Bio. This milestone\nsignificantly advances the clinical development of LBL‑051, Oblenio’s sole\nasset – a CD19×BCMA×CD3 tri‑specific T‑cell engager designed to reset\nthe immune system in patients with severe autoimmune diseases.\n\nLBL‑051 was discovered and engineered using Leads Biolabs’ proprietary\nLeadsBody platform. By simultaneously targeting BCMA, CD19 and CD3, LBL‑051\nis uniquely designed to deplete a broader spectrum of pathogenic B‑cell and\nplasma cell populations, offering the potential for deeper and more durable\nresponses compared to single-target or bispecific approaches. This immune\nreset strategy aims to achieve long‑term drug‑free remission for patients\nsuffering from a range of refractory autoimmune diseases.\n\nPreclinical data presented by Oblenio at the 2026 European Congress of\nRheumatology (EULAR 2026) demonstrated that step-up dosing of LBL‑051\nresulted in complete depletion of peripheral and tissue B‑cells and plasma\ncells in non‑human primates, with consequent emergence of immature,\nnon‑memory B‑cells in the blood upon recovery – findings consistent with\nchanges described in autoimmune patients achieving long-lasting drug-free\nremissions in the clinic. Importantly, the study showed that the treatment did\nnot cause cytokine release syndrome (CRS), including at high exposure levels,\nand demonstrated dose-dependent decreases in peripheral blood immunoglobulins,\nconsistent with plasma cell depletion.\n\nBased on these robust preclinical data, Oblenio is moving rapidly toward\nclinical trial initiation. In conjunction with the financing, Dr. Xiaoqiang\nKang, Founder, Chairman and CEO of Leads Biolabs, will serve as a Board\nObserver of Oblenio, further strengthening the strategic collaboration between\nthe two companies. As the originating innovator, Leads Biolabs will continue\nto provide technical support to Oblenio and will remain eligible for\nsignificant milestone payments and royalties as LBL‑051 advances through\nglobal clinical development and commercialization.\n\nDr. Xiaoqiang Kang commented, “The strong investor interest in Oblenio’s\nSeries B financing validates the potential of our LeadsBody platform to\ngenerate differentiated assets, and we are pleased to see this financing\nsignificantly accelerate LBL‑051’s path to the clinic.”\n\nAbout Leads Biolabs\nFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company\ndedicated to the discovery, development, and commercialization of innovative\ntherapies to address underserved medical needs in oncology, autoimmune, and\nother severe diseases both in China and globally.\n\nLeads Biolabs is a front-runner in next-generation immuno-oncology treatments\nwith a differentiated pipeline of 14 innovative drug candidates, including\nfour clinical-stage drug candidates and one registration-stage asset.\n\nThe Company adopts a science-driven R&D approach and has successfully\nestablished comprehensive R&D capabilities spanning antibody discovery and\nengineering, in vivo and in vitro efficacy evaluation, as well as druggability\nassessment. It has also developed multiple proprietary technology platforms,\nincluding LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager\nplatform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which\nserve as the cornerstone for its continued innovation and have been validated\nby the clinical outcomes of its bispecific antibody portfolios.\n\nLeads Biolabs has established integrated capabilities across early discovery,\ntranslational medicine, clinical development, CMC and business development.\nThe innovative nature and competitive strengths of its drug candidates,\ncoupled with its global perspectives, proactive strategy, and efficient\nclinical validation, have made it an attractive partner for leading industry\nplayers and investment institutions. For more information, please visit\nhttps://en.leadsbiolabs.com/\n\nContact:\nyizi@leadsbiolabs.com\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9R9c4R","title":"Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development","author":"Globe Newswire","ticker":"9887","created":"2026-06-25T10:38:00.097Z","tickers":["9887"],"exchange":"HKEX","article_body":"NANJING, China, June 25, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co.,\nLtd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today\nannounced that its partner company with Aditum Bio, Oblenio Bio\n(“Oblenio”), has successfully closed an oversubscribed $62 million Series\nB financing round. The round was led by Pfizer Ventures, with participation\nfrom Deep Track Capital, GV, and founding investor Aditum Bio. This milestone\nsignificantly advances the clinical development of LBL‑051, Oblenio’s sole\nasset – a CD19×BCMA×CD3 tri‑specific T‑cell engager designed to reset\nthe immune system in patients with severe autoimmune diseases.\n\nLBL‑051 was discovered and engineered using Leads Biolabs’ proprietary\nLeadsBody platform. By simultaneously targeting BCMA, CD19 and CD3, LBL‑051\nis uniquely designed to deplete a broader spectrum of pathogenic B‑cell and\nplasma cell populations, offering the potential for deeper and more durable\nresponses compared to single-target or bispecific approaches. This immune\nreset strategy aims to achieve long‑term drug‑free remission for patients\nsuffering from a range of refractory autoimmune diseases.\n\nPreclinical data presented by Oblenio at the 2026 European Congress of\nRheumatology (EULAR 2026) demonstrated that step-up dosing of LBL‑051\nresulted in complete depletion of peripheral and tissue B‑cells and plasma\ncells in non‑human primates, with consequent emergence of immature,\nnon‑memory B‑cells in the blood upon recovery – findings consistent with\nchanges described in autoimmune patients achieving long-lasting drug-free\nremissions in the clinic. Importantly, the study showed that the treatment did\nnot cause cytokine release syndrome (CRS), including at high exposure levels,\nand demonstrated dose-dependent decreases in peripheral blood immunoglobulins,\nconsistent with plasma cell depletion.\n\nBased on these robust preclinical data, Oblenio is moving rapidly toward\nclinical trial initiation. In conjunction with the financing, Dr. Xiaoqiang\nKang, Founder, Chairman and CEO of Leads Biolabs, will serve as a Board\nObserver of Oblenio, further strengthening the strategic collaboration between\nthe two companies. As the originating innovator, Leads Biolabs will continue\nto provide technical support to Oblenio and will remain eligible for\nsignificant milestone payments and royalties as LBL‑051 advances through\nglobal clinical development and commercialization.\n\nDr. Xiaoqiang Kang commented, “The strong investor interest in Oblenio’s\nSeries B financing validates the potential of our LeadsBody platform to\ngenerate differentiated assets, and we are pleased to see this financing\nsignificantly accelerate LBL‑051’s path to the clinic.”\n\nAbout Leads Biolabs\nFounded in 2012, Leads Biolabs is a clinical-stage biotechnology company\ndedicated to the discovery, development, and commercialization of innovative\ntherapies to address underserved medical needs in oncology, autoimmune, and\nother severe diseases both in China and globally.\n\nLeads Biolabs is a front-runner in next-generation immuno-oncology treatments\nwith a differentiated pipeline of 14 innovative drug candidates, including\nfour clinical-stage drug candidates and one registration-stage asset.\n\nThe Company adopts a science-driven R&D approach and has successfully\nestablished comprehensive R&D capabilities spanning antibody discovery and\nengineering, in vivo and in vitro efficacy evaluation, as well as druggability\nassessment. It has also developed multiple proprietary technology platforms,\nincluding LeadsBody (a CD3 T-cell engager platform), X-body (a 4-1BB engager\nplatform), TOPiKinectics (an ADC platform) and ImBiTDC (a TDC platform), which\nserve as the cornerstone for its continued innovation and have been validated\nby the clinical outcomes of its bispecific antibody portfolios.\n\nLeads Biolabs has established integrated capabilities across early discovery,\ntranslational medicine, clinical development, CMC and business development.\nThe innovative nature and competitive strengths of its drug candidates,\ncoupled with its global perspectives, proactive strategy, and efficient\nclinical validation, have made it an attractive partner for leading industry\nplayers and investment institutions. For more information, please visit\nhttps://en.leadsbiolabs.com/\n\nContact:\nyizi@leadsbiolabs.com\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-25T10:38:00.156067742Z","server_sent_at_ms":1782383880156},"received_at":"2026-06-25T10:38:00.204Z","source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317381/0/en/Leads-Biolabs-Announces-Partner-Oblenio-Bio-s-62-Million-Oversubscribed-Series-B-Financing-to-Advance-Tri-Specific-T-Cell-Engager-LBL-051-for-Autoimmune-Diseases-into-Clinical-Deve.html"},"analysis":{"id":"62283","press_release_id":"72916","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Leads Biolabs' partner Oblenio Bio secured an oversubscribed $62 million Series B financing round led by Pfizer Ventures to advance LBL-051 into clinical development.\n\nThe funding validates the potential of the LeadsBody platform and accelerates the tri-specific T-cell engager program for severe autoimmune diseases without diluting Leads Biolabs shareholders.\n\nLeads Biolabs remains eligible for milestone payments and royalties, while CEO Dr. Xiaoqiang Kang joins Oblenio's board as an observer to strengthen strategic collaboration.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Partner raises $62M from Pfizer Ventures to fund Leads Biolabs-discovered asset, validating platform potential."},"keyFigures":{"dealValueUsd":62000000,"customDimensions":{"drugName":"LBL-051"}},"quotedText":"The strong investor interest in Oblenio’s Series B financing validates the potential of our LeadsBody platform to generate differentiated assets, and we are pleased to see this financing significantly accelerate LBL‑051’s path to the clinic.","namedEntities":{"people":[{"name":"Dr. Xiaoqiang Kang","role":"Founder, Chairman and CEO"}],"products":["LBL-051","LeadsBody platform"],"companies":[{"name":"Leads Biolabs Co., Ltd.","ticker":"9887"},{"name":"Oblenio Bio","relationship":"partner"},{"name":"Aditum Bio","relationship":"partner"},{"name":"Pfizer Ventures","relationship":"investor"},{"name":"Deep Track Capital","relationship":"investor"},{"name":"GV","relationship":"investor"}],"dollarAmounts":[{"amount":"$62 million","context":"Series B financing round"}]},"materialImpact":{"score":3,"reasoning":"The $62M financing by partner Oblenio significantly de-risks the LBL-051 program and validates the Leads Biolabs platform. While no direct capital is raised by the Filer, the milestone/royalty potential and Board Observer role strengthen the partnership's value."},"tickerRelevance":{"others":[],"primary":"9887"},"globalImportance":30,"audienceRelevance":15,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"partner-financing","sectorWeight":"biotech","investorQuality":"Pfizer Ventures"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Leads Biolabs' partner Oblenio Bio secured an oversubscribed $62 million Series B financing round led by Pfizer Ventures to advance LBL-051 into clinical development.\n\nThe funding validates the potential of the LeadsBody platform and accelerates the tri-specific T-cell engager program for severe autoimmune diseases without diluting Leads Biolabs shareholders.\n\nLeads Biolabs remains eligible for milestone payments and royalties, while CEO Dr. Xiaoqiang Kang joins Oblenio's board as an observer to strengthen strategic collaboration.","key_figures":{"dealValueUsd":62000000,"customDimensions":{"drugName":"LBL-051"}},"named_entities":{"people":[{"name":"Dr. Xiaoqiang Kang","role":"Founder, Chairman and CEO"}],"products":["LBL-051","LeadsBody platform"],"companies":[{"name":"Leads Biolabs Co., Ltd.","ticker":"9887"},{"name":"Oblenio Bio","relationship":"partner"},{"name":"Aditum Bio","relationship":"partner"},{"name":"Pfizer Ventures","relationship":"investor"},{"name":"Deep Track Capital","relationship":"investor"},{"name":"GV","relationship":"investor"}],"dollarAmounts":[{"amount":"$62 million","context":"Series B financing round"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-25T10:44:02.797Z","global_importance":30,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"partner-financing","sectorWeight":"biotech","investorQuality":"Pfizer Ventures"}},"durationMs":107400,"modelName":"george-droid-qwen-72b"}}